The options were granted in accordance with Nasdaq Listing Rule 5635(4).
The options have an exercise price of
About
Contact:
Email: mcarrasco@akebia.com
(C) 2023 Electronic News Publishing, source
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.125 USD | -2.17% | -12.20% | -12.90% |
May. 09 | Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M | MT |
The options were granted in accordance with Nasdaq Listing Rule 5635(4).
The options have an exercise price of
About
Contact:
Email: mcarrasco@akebia.com
(C) 2023 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
-12.90% | 241M | |
+8.34% | 115B | |
+13.08% | 107B | |
-12.72% | 22.31B | |
-3.99% | 21.6B | |
-6.95% | 18.23B | |
-39.93% | 17.62B | |
+6.49% | 14.26B | |
+33.62% | 12.37B | |
-28.57% | 8.28B |